● Recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

Condition: Respiratory Syncytial Virus · Sponsor: Sinocelltech Ltd.

PhasePhase 1/Phase 2

Planned participants480

Who can joinAll sexes, 18 Years to 120 Years

Healthy volunteersYes

About this study

This is a randomised, double-blind, placebo-controlled Phase 1/2 clinical trial to evaluate the safety, tolerability and immunogenicity of recombinant respiratory syncytial virus in participants aged 18 years and older.

This description comes directly from the study's public registry record.

Talk to the study team

Yang Xinjie, Doctor · 86+010-58628288 · xinjie_yang@sinocelltech.com

Always discuss trial participation with your own doctor first.

Locations (2)

Hebei Zhongshiyou Central Hospital	Langfang, Hebei, China	Recruiting
Luzhou Center for Disease Control and Prevention	Luzhou, Sichuan, China	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06754605